Lyell Immunopharma更新Lyl273在复发或难治性转移性结直肠癌中的安全性数据,并将一期试验扩展为一/二期

美股速递
Jun 08

Lyell Immunopharma公司宣布,已就其候选药物Lyl273在治疗复发或难治性转移性结直肠癌患者中的安全性概况提供了最新信息。同时,公司决定将原计划的一期临床试验方案修订并扩展为一/二期试验。此举旨在进一步评估该疗法的安全性与初步疗效,为后续的临床开发路径收集更全面的数据。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10